Brain
Post-Treatment Brain MRI: When Enhancement Lies
Fellowship-level neuroradiology teaching by E. Brooke Schrickel, MD. Open this topic in the interactive reading room →
Watch · concise explainerWhen enhancement lies
Core clinical idea
In the treated brain, enhancement lies in both directions — more isn't always tumor, less isn't always response. Read post-contrast enhancement through three axes (time since treatment, drug class, rCBV technique) and let clinical status break the tie before calling progression or response.
Bottom line
Post-treatment enhancement lies both ways — read it through time, drug class, and corrected rCBV before calling progression or response.
Core workstation questions
- How long since radiation/chemo — am I in the pseudoprogression window or the radiation-necrosis window?
- Is the patient on an antiangiogenic (Avastin), or recently off it?
- Is this the rCBV-corrected map, or an uncorrected map that under-calls viable tumor?
- Do rCBV and spectroscopy (elevated choline) corroborate 'active tumor'?
- Is this an MGMT-methylated tumor, biasing early new enhancement toward pseudoprogression?
What changes reporting / management
- Place every post-treatment scan on the treatment clock before calling progression; early + chemoradiation favors pseudoprogression, late + prior radiation favors necrosis.
- On an antiangiogenic, do not credit reduced enhancement/edema as response without corroboration (pseudoresponse); rebound after holding the drug is a BBB effect, not new progression.
- State which rCBV map was used and use the corrected map in the treated brain.
- Use worsening clinical status as the tiebreaker imaging can't always resolve.
Practical traps
- Calling progression on new enhancement within the early pseudoprogression window (esp. with temozolomide).
- Reading reduced enhancement on Avastin as tumor shrinkage (pseudoresponse).
- Misreading post-Avastin-holiday enhancement/edema rebound as new progression.
- Using an uncorrected rCBV map and under-calling viable tumor (false negative from leakage).
- Ignoring MGMT methylation status, which raises the prior for pseudoprogression.
Teaching pearls
- Reduced enhancement on Avastin is a BBB effect, not a response.
- Put every post-treatment scan on the treatment clock before you call progression.
- Verify the rCBV map is corrected — uncorrected under-calls viable tumor.
- MGMT-methylated? Bias early new enhancement toward pseudoprogression.
Source lectures
- Post-Treatment Brain MRI – Pitfalls
Educational material for radiology residents and neuroradiology fellows. Nothing here drives individual patient care, and it contains no patient data.